1. Home
  2. AKBA vs ALCO Comparison

AKBA vs ALCO Comparison

Compare AKBA & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.93

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo Alico Inc.

ALCO

Alico Inc.

HOLD

Current Price

$41.08

Market Cap

297.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
ALCO
Founded
2007
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
297.9M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
AKBA
ALCO
Price
$0.93
$41.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$4.67
$44.00
AVG Volume (30 Days)
5.7M
13.3K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
0.49%
EPS Growth
93.94
N/A
EPS
N/A
1.03
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$39.81
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$30.95
52 Week High
$4.08
$45.01

Technical Indicators

Market Signals
Indicator
AKBA
ALCO
Relative Strength Index (RSI) 38.26 51.45
Support Level $0.88 $39.94
Resistance Level $1.56 $42.23
Average True Range (ATR) 0.07 0.77
MACD 0.00 0.08
Stochastic Oscillator 43.33 59.24

Price Performance

Historical Comparison
AKBA
ALCO

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.

Share on Social Networks: